Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Vivos Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was $11.22 Mil. Vivos Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $11.80 Mil.
Therefore, Vivos Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.95.
Vivos Therapeutics Liabilities-to-Assets Historical Data
The historical data trend for Vivos Therapeutics's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vivos Therapeutics's Liabilities-to-Assets
For the Medical Devices subindustry, Vivos Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics's Liabilities-to-Assets Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Vivos Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Vivos Therapeutics Liabilities-to-Assets Related Terms
Thank you for viewing the detailed overview of Vivos Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivos Therapeutics (Vivos Therapeutics) Business Description
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VVOS has been successfully added to your 